Key facts
- This page summarizes Suping (sue) Cheung's Form 4/A - Amendment filing for MARRONE BIO INNOVATIONS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Mar 2022, 17:32.
Suping (sue) Cheung - 07 Feb 2022 Form 4/A - Amendment Insider Report for MARRONE BIO INNOVATIONS INC
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 07 Feb 2022
- Net transaction value
- +$41,127
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 18 Mar 2022, 17:32:46 UTC
- Original report date
- 09 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Linda V. Moore, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Suping (sue) Cheung filed Form 4/A - Amendment for MARRONE BIO INNOVATIONS INC on 18 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$41,127.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBII
transaction
Common Stock
Award
- Transaction value
- $41,127
- Shares
- +65,064
- Change %
- Price
- $0.6321
- Shares after
- 65,064
- Date
- 07 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBII
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +185,555
- Change %
- Price
- $0.000000
- Shares after
- 185,555
- Date
- 07 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,555
- Exercise price
- $0.6321
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Suping (sue) Cheung is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On February 7, the reporting person was granted 65,064 restricted stock units, which represent a contingent right to receive one share of Issuer's common stock. The restricted stock units vest pursuant to the Vesting Schedule (as defined in footnote (2)) and are delivered to the reporting person upon vesting.
Footnote F2
The awards vest in equal monthly installments over three years, subject to the recipient's continued employment by the Issuer through the applicable vesting date, provided that, in lieu of the terms of any change in control agreement in place between the Issuer and the reporting person, in the event that the reporting person resigns for Good Reason (as defined in the recipient's change in control agreement) or is terminated without Cause (as defined in recipient's change in control agreement) within twelve months of a Change in Control (as defined in recipient's change in control agreement), 50% of the unvested portion of the awards will become immediately vested (the "Vesting Schedule").
Footnote F3
The original Form 4, filed on February 9, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misstated the expiration date as February 6, 2025.